Benefit of Aspirin After A-Fib Ablation Questioned

This article originally appeared here.
Share this content:
Benefit of Aspirin After A-Fib Ablation Questioned
Benefit of Aspirin After A-Fib Ablation Questioned

FRIDAY, Sept. 1, 2017 (HealthDay News) -- For atrial fibrillation (AF) ablation patients undergoing their index ablation, long-term aspirin therapy is associated with increased rates of bleeding and may not lower risk of stroke, according to a study published online Aug. 28 in the Journal of Cardiovascular Electrophysiology.

Victoria Jacobs, Ph.D., from the Intermountain Medical Center Heart Institute in Murray, Utah, and colleagues included 4,124 AF ablation patients undergoing index ablation in a retrospective observational study. The authors compared one- and three-year outcomes for patients receiving aspirin or warfarin as long-term therapies versus no therapy.

The researchers found that patients with higher CHADS2VASc scores were more likely to be female and have hypertension, diabetes mellitus, heart failure, or vascular disease (P < 0.0001 for all). Overall, 5.9, 18.6, and 75.5 percent of patients were on warfarin, aspirin, and no therapy at three years, respectively; with advancing CHA2DS2VASc score, the occurrences of cerebrovascular accident/transient ischemic attack (CVA/TIA) were 1.4, 3.0, and 3.9 percent, respectively (P < 0.0001); gastrointestinal bleeding was 0.8, 1.9, and 1.1 percent, respectively (P = 0.06); and genitourinary bleeding was 1.7, 2.8, and 2.1 percent, respectively (P = 0.008). Compared with no therapy or warfarin therapy, aspirin therapy was associated with increased risk for both CVA/TIA and across all CHA2DS2VASc scores.

"After catheter ablation, low risk patients do not benefit from long-term aspirin therapy, but are at risk for higher rates of bleeding when compared to no therapy or warfarin," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »